The phase 3 trial of Takeda protease inhibitor Ninlaro (ixazomib) reaches the main end of the trial

today, Takeda(http://announced that its protease inhibitor Ninlaro (ixazomib) as a first-line maintenance therapy, in the treatment of adult patients with multiple myeloma (MM) without stem cell transplant ation almanac (http:// in the phase
3 experimental(http://, so that patients have no progress(PFS) significantly improved to reach the main end of the trialAbout Ninlaro
Ninlaro is the first oral protease inhibitor approved by theFDA(http://, which selectively binds to psMB5 subases of proteases and inhibits its activityPreviously, it has been approved by the U.SFDA and two otherdrugs(http://used to treat MM patients who have received at least one treatment 　　Currently, Ninlaro is also working with other drugs to treat MM patients in several key clinical trials 　　In tourmaline-MM4, a phase 3 clinical trial of a randomized, double-blind, placebo-controlled group, 706 newly diagnosed adult patients who had not received stem cell transplant therapy had completed the initial treatment for 6 to 12 months prior to participating in the trial and received ninlaro or placebo treatment after partial remission 　　The results showed that PFS in patients treated with Ninlaro showed a statistically significant improvement to reach the main endpoint of the trial compared to the placebo group The study was designed to validate the concept of conversion maintenance therapy, in which the maintenance therapy drugs used in trials differ from those used in the initial induction therapy Detailed data on the trial will be published at the (http:// of future medical meetings